Medication & Medical Management

The FDA says BD and CareFusion are removing certain Alaris infusion sets after updated testing found performance problems. No serious injuries or deaths were reported as of Aug. 19, 2026.

• Three Hearts Home Team
• October 8, 2026

Projected 2027 Medicare costs include higher Part D limits and a $209.50 Part B premium; insurers may cut plans and benefits.

• Three Hearts Home Team
• October 7, 2026

A KFF Health News report urges older adults and caregivers to review prescriptions regularly as medication needs and research change.

• Three Hearts Home Team
• October 6, 2026

A Michigan family says a memory care facility pressured them to medicate their mother. The facility denies the allegations; a trial is scheduled.

• Three Hearts Home Team
• October 2, 2026

FDA approved AbbVie’s once-daily pill Juvmo (tavapadon) on Sept. 25 for early and later-stage Parkinson’s, expected in U.S. pharmacies in October 2026.

• Three Hearts Home Team
• October 1, 2026

A 400-person study found more time in range and greater glucose variability were each associated with better next-day quality of life.

• Three Hearts Home Team
• September 30, 2026

CMS is seeking input on whether clinical AI could support Medicare wellness visits, while keeping care tied to Medicare-enrolled providers.

• Three Hearts Home Team
• September 30, 2026

A University of Florida study found an association between glucosamine use and MCI progression, but it does not show the supplement causes dementia.

• Three Hearts Home Team
• September 29, 2026

Interest is rising in a question about FDA advisors and a cancer blood test, but the available source does not confirm a meeting or decision.

• Three Hearts Home Team
• September 26, 2026